Altimmune Announces Proposed Underwritten Public Offering of Securities

GAITHERSBURG, Md., April 22, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced it has commenced an underwritten public offering of shares of its common stock and accompanying common stock warrants to purchase an equivalent number of shares of its common stock (or pre-funded warrants in lieu thereof), and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock and accompanying common stock warrants to purchase shares of its common stock (or pre-funded warrants in lieu thereof). All of the shares, pre-funded warrants and accompanying common stock warrants to be sold in the proposed public offering are being offered by Altimmune. The proposed public offering is subject to market and other conditions, and there can be no assurance as to whether or when the proposed public offering may be completed or as to the actual terms of the offering.